tioconazole

Trade name: tz-3

Small moleculeapproved

Approved

Feb 18, 1983

Tioconazole is an antifungal medication of the imidazole class used to treat infections caused by a fungus or yeast. Tioconazole is a broad-spectrum imidazole antifungal agent that inhibits the growth of human pathogenic yeasts. Tioconazole exhibits fungicidal activity in vitro against Candida albicans, other species of the genus Candida, and against Torulopsis glabrata. Tioconazole prevents the growth and function of some fungal organisms by interfering with the production of substances needed to preserve the cell membrane. This drug is effective only for infections caused by fungal organisms. Tioconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane. In this way, tioconazole inhibits ergosterol synthesis, resulting in increased cellular permeability. Tioconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms and the uptake of purine, impair triglyceride and/or phospholipid biosynthesis, and inhibit the movement of calcium and potassium ions across the cell membrane by blocking the ion transport pathway known as the Gardos channel. Side effects (for the women's formulas) may include temporary burning/irritation of the vaginal area, moderate drowsiness, headache similar to a sinus headache, hives, and upper respiratory infection. — NCATS

Clinical trial activity

3 trials · 4 clinical orgs · 3 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
2

Earliest trial started Apr 30, 2019 (NCT03839875)

Timeline

1980s

  1. Feb 18, 1983

    Pfizer — Earliest FDA Approval

  2. Feb 18, 1983

    Pfizer — NDA Organization

1990s

  1. Feb 11, 1997

    Bristol-Myers Squibb — NDA Secondary Org

2000s

  1. Nov 21, 2001

    Perrigo — Marketing Organization

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedFeb 18, 1983

Chemistry & pharmacology

Loading structure…

SMILES

ClC1=C(COC(CN2C=CN=C2)C3=CC=C(Cl)C=C3Cl)C=CS1
Mol. weight
387.711 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Over the Counter

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 1h-imidazole, 1-(2-((2-chloro-3-thienyl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-
  • gyno-trosyd
  • monistat 1-day
  • mykontral
  • tioconazol
  • tioconazol
  • tioconazole
  • tioconazole
  • tioconazole
  • tioconazole
  • tioconazole
  • tioconazole
  • tioconazole
  • tioconazole
  • tioconazole
  • tioconazolum
  • tioconazolum
  • trosderm
  • trosid
  • trosyd
  • trosyl
  • trosyl
  • trosyl
  • tz-3
  • tz-3
  • tz-3
  • uk 20,349
  • uk-20349
  • uk-20349
  • uk-20349
  • uk-20,349
  • uk-20,349
  • uk-20,349
  • uk-20,349
  • uk-20,349
  • vagistat
  • vagistat
  • vagistat
  • vagistat-1
  • vagistat-1
  • vagistat-1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05999474Phase 4Sep 1, 2022Cairo University
NCT06056947Phase 3Jul 20, 2020Ege University, Exeltis, MonitorCRO
NCT03839875Phase 4Apr 30, 2019Exeltis, MonitorCRO
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ExeltisFor profit2122019
MonitorCROFor profit2022019
Cairo UniversityAcademic/Hospital1112022
Ege UniversityAcademic/Hospital1112020
4 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
Bristol-Myers SquibbFor profitNDA2Feb 11, 1997
PerrigoFor profitMKTGNov 21, 2001
PfizerFor profitNDAFeb 18, 1983